Outcomes among patients with end-stage liver disease who are coinfected with HIV and hepatitis C virus.
In at-risk populations, shared routes of transmission lead to high rates of concordance between infection with human immunodeficiency virus (HIV) type 1 and hepatitis C virus (HCV). In the era of highly active antiretroviral therapy (HAART), end-stage liver disease (ESLD) has emerged as a leading cause of mortality in coinfected patients. HAART-related toxicities have been implicated, especially when given to patients with viral hepatitis. Rates of response to treatment for HCV infection in coinfected patients continue to lag behind those in monoinfected patients, even with the advent of pegylated interferons. Liver transplantation has been approached with caution in this population because of concern about the sequelae of immunosuppression and HAART-related hepatotoxicity, and results have been conflicting. Clinical and serological markers of ESLD in coinfected patients, management of cirrhosis, and the appropriateness of transplantation are discussed.
Neff
Guy W
GW
Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA. guy.neff@uc.edu
Shire
Norah J
NJ
Rudich
Steven M
SM
D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D019468:Disease Management; D018450:Disease Progression; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006526:Hepatitis C / Q000150:complications*; D006801:Humans; D007676:Kidney Failure, Chronic; D008103:Liver Cirrhosis / Q000150:complications* / Q000175:diagnosis / Q000628:therapy; D017093:Liver Failure / Q000209:etiology / Q000401:mortality*; D016031:Liver Transplantation / Q000941:ethics / Q000706:statistics & numerical data; D016896:Treatment Outcome